By Dr. Stephen Houldsworth - Global Head, Small Molecules Platform, CordenPharma;
Dr. John Cameron - Global Head, Injectables Platform, CordenPharma;
Dr. Mimoun Ayoub - Global Head,Peptides Platform, CordenPharma;
Dr. Matthieu Giraud - Global Head, Lipids & LNPs Platform, CordenPharma
CordenPharma expands global capacity, investing in key platforms to deliver
fully-integrated solutions across multiple therapeutic modalities, from drug substance
to drug product and packaging.
CordenPharma understands today’s pharma market
demands and is investing in key technology platforms
- Small Molecules & Highly Potent Drug Substance and Drug
Products, Injectables, Peptides, Lipids & LNPs - to provide
customers with true end-to-end support. With expanded
capacity, upgraded infrastructure, and an integrated global
network across Europe and the US, we help innovators
reduce complexity, mitigate risk, and accelerate timelines,
ensuring efficient progress from early development through
commercial supply for their patients worldwide...
Read in the digital edition
- PHARMAnetwork magazine n° 67, page 30
